bioAffinity Technologies, Inc 8-K, filed Nov 19, 2026
bioAffinity Technologies, Inc. (BIAF)
About this 8-K
bioAffinity Technologies, Inc filed this 8-K on November 19, 2026.
bioAffinity Technologies reported record CyPath Lung testing volume in October 2026, the highest monthly volume for its noninvasive lung cancer test. Q3 CyPath Lung test unit sales rose 109% year to date over 2025, and ordering physicians increased 89%. AI summary
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
|
(Nasdaq Capital Market) | |||
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On November 19, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) released a newsletter providing an overview of certain recent developments.
A copy of the newsletter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Forward-Looking Statements
Certain statements in the newsletter constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully commercialize CyPath® Lung, risks related to the regulatory environment for laboratory developed tests, the Company’s ability to obtain sufficient financing to fund operations and development; achieve and sustain physician adoption, test utilization and reimbursement; convert distribution access and market interest into orders and revenue; successfully conduct research and clinical validation and demonstrate safety, efficacy and clinical utility, as applicable; obtain and maintain any required regulatory authorizations and comply with evolving regulatory requirements; maintain laboratory capacity and quality; execute collaborations and distribution arrangements; protect and enforce intellectual property; compete effectively; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of the newsletter are cautioned not to place undue reliance on any forward-looking statements. The information in the newsletter are provided only as of the date of the newsletter, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in the newsletter, except as may be required by applicable securities laws.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit Number |
Description | |
| 99.1 | Company Newsletter, 2nd Edition, Fall / Winter 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 19, 2026 | BIOAFFINITY TECHNOLOGIES, INC. | |
| By: | /s/ Maria Zannes | |
| Name: | Maria Zannes | |
| Title: | President and Chief Executive Officer | |
| -3- |
Exhibit 99.1
bioAffinity Technologies newsletter, 2nd Edition, Fall/Winter 2026
![]() |
Company Newsletter
2nd Edition
Fall/Winter 2026
Nasdaq: BIAF |
Message from our CEO

We look forward to an exciting and productive holiday season at bioAffinity Technologies as we continue to expand the reach and potential of our innovative technologies. CyPath Lung continues to gain commercial momentum, with growing adoption by physicians and strong year-over-year growth in test volume. At the same time, we are opening important new opportunities to bring CyPath Lung to more patients, including our nationwide federal healthcare distribution agreement with AvMEDICAL and our expanding engagement with physicians, administrators and leaders serving our nation’s veterans.
We are also advancing the science behind CyPath Lung, including its potential use in the surveillance of lung cancer survivors, and developing precision diagnostics to characterize lung inflammation in patients with asthma and COPD that may enable physicians to make more informed treatment choices for individual patients. We also see promising results of our research to advance our therapeutic discoveries using self-delivering, stabilized siRNA technology to investigate whether skin cancer cells can be targeted while preserving healthy cutaneous tissue — representing a potentially significant advancement in selective cancer treatment. The asthma/COPD diagnostic and siRNA therapeutic programs remain in research and development, distinct from the current commercialization of CyPath Lung.
Our progress is a testament to the commitment and expertise of the bioAffinity team as we continue advancing innovative solutions to support earlier disease detection, more informed clinical decisions and better patient outcomes. We are excited about the opportunities ahead and look forward to keeping you informed as we reach new milestones.
Sincerely,
Maria Zannes
President and CEO
| -1- |
CyPath Lung Commercial Expansion Continues
bioAffinity Technologies reported record testing volume in October. CyPath Lung test unit sales in Q3 doubled year to date over 2025, with solid gains in physician utilization and recurring orders.
Together, the 109% increase in test unit sales, 89% increase in ordering physicians and 48% growth in orders from existing physicians indicate broader physician adoption and increased repeat utilization.

New Podcast: Physicians Take the Stage to Discuss the Benefits of CyPath Lung
Tune in to CyPath Lung Connect, our podcast and educational forum series that brings together leaders in pulmonology, oncology, and lung health to discuss early lung cancer diagnosis, screening guidelines, and clinical applications. Our most recent podcast, From CT to Sputum: Rethinking Lung Nodule Risk in Veterans, offers greater insight into the challenges veterans face with disproportionately high rates of lung cancer. |
Listen and follow here |
| -2- |
Expanding Awareness, Access and Use of CyPath Lung for U.S. Veterans
Lung cancer weighs heavily on the veteran community. The U.S. Department of Veterans Affairs (VA) reports that approximately 7,700 veterans are diagnosed with lung cancer each year.
Our new nationwide federal healthcare partnership with AvMEDICAL provides an important pathway to expand access to CyPath Lung across VA medical centers and other federal healthcare facilities. In September, bioAffinity and AvMEDICAL introduced CyPath Lung to more than 300 physicians, healthcare professionals and VA leaders at the 2026 NAVREF Annual Conference, advancing awareness of our noninvasive test and its potential benefits for veterans at risk for lung cancer. The agreement provides an additional channel for access through the federal healthcare system; access through this channel does not itself represent completed sales.
Advancing Development of Precision Diagnostics for Asthma and COPD
According to the CDC, asthma and COPD affect more than 40M Americans and 650M people worldwide. The global therapeutics market for these conditions was valued at $92B in 2024 and is projected to reach $155B by 2030.
Our pipeline includes noninvasive diagnostics being developed to potentially help physicians select treatments for asthma and COPD. We’re combining Pictor’s multiplex technology with bioAffinity’s proprietary flow cytometry+AI platform and selected biomarkers to investigate whether these technologies could help physicians more precisely manage two of the world’s most common respiratory diseases. We are working on next-generation diagnostic tests to characterize lung inflammation and detect biologic drug targets in sputum for asthma and COPD therapies.
Announcing Newly Issued Patents
| bioAffinity Technologies is expanding its global patent estate that protects the technology underlying CyPath Lung and its diagnostic platform. With additional patent protection now in Hong Kong, China and Japan, the Company is strengthening its intellectual property portfolio of 14 issued and 24 pending diagnostic patents and supporting CyPath Lung’s positioning to enter Asian markets. | ![]() |
| -3- |
Newly Released Interviews Highlight Growth
From record CyPath Lung testing and real-world patient cases to new markets for the Company’s platform technology, CEO Maria Zannes discusses what’s next for bioAffinity Technologies, including increasing sales, meeting the needs of the federal healthcare market, clinical research and how the Company’s flow cytometry+AI platform is being developed to serve the needs of multi-billion-dollar markets.

(click on image or link to play video)
CyPath Lung Testing Fuels Growth Ambitions
Proactive Investor News

(click on image or link to play video)
| -4- |
bioAffinity Technologies Reports 200% Revenue Growth, Expands Lung Diagnostics Strategy
Proactive Investor News

(click on image or link to play video)
bioAffinity Technologies Advances CyPath Lung Toward Broader Clinical and Federal Healthcare Adoption
The Market Link
Get Caught Up on Recent Company News
(click on date to read release)
bioAffinity continues to deliver a steady stream of Company news, including:
Nov. 11
A record number of CyPath Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test
Nov. 6
Continued momentum in CyPath Lung commercialization in third quarter 2026
Oct. 15
Our Chief Medical Officer presents new perspectives on CyPath Lung’s use for cancer risk assessment at CHEST 2026
| -5- |
Oct. 13
Positive research results spur development of our new test measuring asthma and COPD-related lung inflammation and drug-related receptors
Oct. 9
Announced $4 million raised in a registered direct financing of common stock and concurrent private placement priced at-the-market under Nasdaq rules
Oct. 8
Japan sends notification of its intent to issue patent protection for our noninvasive CyPath Lung and the AI-built algorithm
Oct. 6
Announcing over 100% growth in CyPath Lung sales through third quarter 2026
Sept. 30
bioAffinity Technologies joins its distribution partner AvMEDICAL in presenting to physicians and U.S. veterans in Washington, D.C.
Connect with bioAffinity Technologies
bioaffinitytech.com | cypathlung.com
This newsletter may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. For a discussion of risks and uncertainties, please refer to bioAffinity Technologies’ filings with the Securities and Exchange Commission (SEC).
CyPath® Lung is a registered trademark of bioAffinity Technologies, Inc.
View email in browser
bioAffinity Technologies, Inc. 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 · USA
update your preferences or unsubscribe
| -6- |


